Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. 📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

Applications are now open for the IMS Translational Research Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/YpOf50Xmll7

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

Applications are now open for the IMS Career Development Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/9Y8S50XmljS

Applications are now open for the IMS Translational Research Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/2Fqu50XmllI

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. 📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

Applications are now open for the IMS Translational Research Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/Q5vK50XeemR

Applications are now open for the IMS Career Development Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/MzL650XegkS

🚨There's still time! 🚨On demand registration is still available for the complimentary Novel Immune Therapies Workshop in conjunction with #DGHO. ➡️bit.ly/4poxPuF

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

Applications are now open for the IMS Career Development Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/MzL650XegkS

Applications are now open for the IMS Translational Research Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/Q5vK50XeemR

Applications are now open for the IMS Career Development Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/2rZy50XegkQ

Applications are now open for the IMS Translational Research Award. Be sure to apply by January 30, 2026. ➡️https://ow.ly/Q5vK50XeemR

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

The IMS joins the global myeloma community in mourning the passing of our colleague, Dr Brian Durie, co-founder of @imfmyeloma.bsky.social. He will be forever remembered for his groundbreaking contributions to myeloma research and his unwavering dedication to patient care. ow.ly/zbUt50XbKzb

🚨Register now! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! ➡️bit.ly/4poxPuF

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. 📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

Check out IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community. Listen, download, and share here ➡️ https://rb.gy/tw8r1v

🚨Register now! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! ➡️bit.ly/4poxPuF

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

There is still time to register for our complimentary webinars on Relapsed/Refractory Multiple Myeloma! 📅 Oct 8 | 6–7:30 PM ET (East Coast) 📅 Oct 15 | 6–7:30 PM PT (West Coast) Register: bit.ly/4659Tov

Check out IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community. Listen, download, and share here ➡️ https://rb.gy/tw8r1v

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. 📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

Save the Date!🗓️Join the IMS March 27-28, 2026 for the 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop in Boston. More details coming soon.

🚨Register now! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! ➡️bit.ly/4poxPuF

Join us for a complimentary IMS Webinar on Relapsed/Refractory Multiple Myeloma! 📅 Oct 8 | 6–7:30 PM ET (East Coast) 📅 Oct 15 | 6–7:30 PM PT (West Coast) Register: bit.ly/4659Tov

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. 📍Belgrade, Serbia & On-demand | Mar 13–14, 2026

🚨We are just under 6 weeks away! 🚨Join IMS for our complimentary Novel Immune Therapies Workshop on Oct 27 in conjunction with #DGHO. On-demand registration is also available, so reserve your spot today! bit.ly/4poxPuF

Don't forget, you can still access #IMS25 meeting content. If you registered for either in-person or virtual this year, log in to the virtual platform to review all recorded sessions.

Thank you to everyone who joined #IMS25, both in person and virtually. Save the date for next year's conference, taking place September 23-26 in Glasgow, Scotland. We look forward to seeing you in 2026!

Day 4 highlights from the 22nd Annual IMS Meeting! #IMS25

Three myeloma experts made engaging & persuasive arguments for the supremacy of ADCs, bispecifics, and CAR-Ts for treating MM. No clear winner in this dynamic debate but having these options counts as a win for the race to cure myeloma! #IMS25

Xavier Leleu, MD, PhD, gave a moving tribute to Frank Bridoux, MD, PhD, friend & colleague at the University Hospital Poitiers. Dr. Bridoux’s expertise included cast nephropathy & glomerulopathies, and seminal contributions in MGRS/MGCS. #IMS25

✨Join us in Hall FG for the conclusion of #IMS25! 12:00 PM ➡️ Highlights of the 2025 Annual Meeting 1:00 PM ➡️ Debate on ADCs, Bispecifics or CART 2:00 PM ➡️ Closing Ceremony

Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25

Coming up at 10:00 AM in Hall FG: Future Targets and New Modalities of Therapy #IMS25

Don’t miss the upcoming abstract sessions at 9:00 AM: 📍Room 701 → Abstract Session 9 📍Room 718 → Abstract Session 10

Congratulations to this year's Young Investigator Award recipients at #IMS25.

It’s time for the morning abstracts! #IMS25 📍 Room 701 → Abstract Session 7 📍 Room 718 → Abstract Session 8

It’s the final day of #IMS25! Check the program for today’s highlights and don’t miss the Debate on ADCs, Bispecifics or CART later today! bit.ly/3K8T4QU

Another inspiring day of research and community at #IMS25

Day 3 highlights from the 22nd Annual IMS Meeting! #IMS25

A multi-stakeholder panel discussed a recent EMA-IMS-EHA survey on the attitudes of clinicians and regulators on MRD as an efficacy endpoint in myeloma, nuances of US & EU perspectives, & transplant-eligibility for patient stratification. #IMS25

Josefine Krüger, MD, IMS Riney CD Awardee, identified a previously unknown cereblon-independent mechanism of proteasomal degradation of IKZF1 (Ikaros) transcription factor, a key target of immunomodulatory drugs. #IMS25

With support from the Paula and Rodger Riney Foundation, the IMS has now funded 89 Translational and Career Development Awards, totaling $16 million over the past 5 years, in 66 Institutions across 25 countries. --Bobby Sandage, Jr, PhD #IMS25

Mala Shanmugam, PhD, IMS Riney TR Awardee, spoke about the impact of elevated heme exposure on modulation of T cell behavior and the balance between exhaustion and effector memory/terminally differentiated phenotypes. #IMS25

The IMS and the global myeloma community is deeply appreciative of the generosity, tireless dedication, and enduring support of Paula and Rodger Riney, and the Paula and Rodger Riney Foundation. #IMS25

Coming up at 5:30 PM📍Hall FG → Industry Symposium supported by Gilead & Kite and Arcellx. #IMS25